Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isobel Pearson

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Economic Modeling Considerations for Rare DiseasesIsobel Pearson, Ben Rothwell, Andrew Olaye, et al.
Diagnostic Pathology|February 1, 2020
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatmentTina Krieger, Isobel Pearson, Judith Bell, et al.
Journal of Medical Economics|September 6, 2013
A systematic literature review of utility weights in wet age-related macular degenerationIsobel Pearson, Catherine Rycroft, Adam Irving, et al.
Pharmacoeconomics|November 1, 2015
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in CanadaWilliam Herring, Isobel Pearson, Molly Purser, et al.
Neurology and Therapy|June 1, 2023
A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future AdvancementsAmir Abbas Tahami Monfared, N T Nhan Phan, Isobel Pearson, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Economic Modeling Considerations for Rare DiseasesIsobel Pearson, Ben Rothwell, Andrew Olaye, et al.
Diagnostic Pathology|February 1, 2020
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatmentTina Krieger, Isobel Pearson, Judith Bell, et al.
Journal of Medical Economics|September 6, 2013
A systematic literature review of utility weights in wet age-related macular degenerationIsobel Pearson, Catherine Rycroft, Adam Irving, et al.
Pharmacoeconomics|November 1, 2015
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in CanadaWilliam Herring, Isobel Pearson, Molly Purser, et al.
Neurology and Therapy|June 1, 2023
A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future AdvancementsAmir Abbas Tahami Monfared, N T Nhan Phan, Isobel Pearson, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 1